Premium
Cadila shares up 3 pct on USFDA nod
Cadila Healthcare rose more than 3 per cent after the company said it got US FDA approval to conduct phase-I trials for a diabetes drug.
Shares of Cadila Healthcare rose more than 3 per cent after the company said it got US FDA approval to conduct phase-I trials for a diabetes drug.
At 11.12 a.m.,shares of the company were up 2.63 per cent at Rs 824.
You have exhausted your
monthly limit of free stories.
Read more stories for free
with an Express account.
This story requires a subscription
Select a plan and use DIWALI10 code to get 10% extra off
This premium article is free for now.
Register to continue reading this story
This story requires a subscription
Select a plan and use DIWALI10 code to get 10% extra off
This content is exclusive for our subscribers.
Subscribe now to get unlimited access to The Indian Express exclusive and premium stories.
